Background : Many recent results of clinical trials show that pre-operative concurrent chemoradiotherapy and surgical resection could increase the survival of N2 positive stage ⅢA non-small cell lung cancer.
Material and Method : Thirty-one patients who underwent preoperative concurrent chemoradiotherapy for N2 positive stage ⅢA non-small-cell lung cancer from May 1997 to April 1999 were entered into the study. Mean age was 61 yrs(43∼70yrs), There were 24 men and 7 women. The confirmation of N2 disease were achieved through mediastinoscopic biopsy(24) and CT scans(7). Induction was achieved by tow cycles of cisplatin and etoposide (EP) plus concurrent chest radiotherapy to 45 Gy. Resections were done at 3 weeks after the completion of preoperative concurrent chemoradiotherapy. Resections were performed in 23 patients, excluding 5 refusals and 3 distant metastasis.
Result : All patients were completed the thoracic radiotherapy except one who had distant metastasis. Twenty three patients were completed the planned 2 cycles of EP chemotherapy, and 8 patients were received only 1 cycle for severe side effects(6), refusal(1), and distant metastasis(1). There was one postoperative mortality, and the cause of death was ARDS. Three patients who had neutropenic fever and one patient who had radiation pneumonitis were required admission and treatment. Esophagitis was the most common acute side effect, but relatively well-tolerated in most patients. The completion rate of concurrent chemoradiotherapy was 74％, resection rate was 71％, pathologic complete remission rate was 13.6％, and pathologic down-staging rate was 68％.
Conclusion : Morbidity related to each treatment was acceptable and many of the patients have benefited down staging of its disease. Further prospective, preferably randomized, clinical trials of larger scale may be warranted to confirm the actual benefit of preoperative concurrent chemoradiotherapy and surgical resection in n2-positive stage ⅢA non-small cell lung cancer.
|